On 7 June shares in Biogen, a US biotechnology company, soared by 64%. America’s Food and Drug Administration (FDA) had just approved Biogen’s Aducanumab, the first drug for Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback